Best Practice & Research Clinical Rheumatology
Volume 23, Issue 4 , Pages 469-480, August 2009

Respiratory manifestations of systemic lupus erythematosus: old and new concepts

  • José María Pego-Reigosa, MD, PhD, Consultant Rhumatologist, Doctor

      Affiliations

    • Rheumatology Section, Hospital do Meixoeiro (Complexo Hospitalario Universitario de Vigo), Alto do Meixoeiro s/n, 36200 Vigo (Pontevedra), Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34 986229912; Fax: +34 986811169.
  • ,
  • Dina A. Medeiros, MD, Doctor

      Affiliations

    • Rheumatology Department, Portuguese Institute of Rheumatology, R Beneficência 7, 1050-034 Lisbon, Portugal
  • ,
  • David A. Isenberg, MD, FRCP, Professor of Rheumatology

      Affiliations

    • Centre for Rheumatology Research, University College of London Division of Medicine, Room 331, 3rd Floor, The Windeyer Building, 46 Cleveland Street, London, W1T 4JF, UK

The respiratory system is commonly involved in systemic lupus erythematosus. Lung disorders are classified as primary (due to lupus) and secondary to other conditions. Pleuritis and pulmonary infections are the most prevalent respiratory manifestations of each type. Other infrequent manifestations include interstitial lung disease, acute lupus pneumonitis, diffuse alveolar haemorrhage, pulmonary arterial hypertension, acute reversible hypoxaemia and shrinking lung syndrome. Even when current diagnostic tests contribute to an earlier diagnosis, the treatment of these manifestations is based on clinical experience and small series. Larger controlled trials of the different therapies in the treatment of those lung manifestations of lupus are needed. Overall malignancy is little increased in lupus, but lung cancer and non-Hodgkin's lymphoma are among the most frequent types of cancer found in these patients. As survival in lupus patients has improved over recent decades, avoiding pulmonary damage emerges as an important objective.

Keywords: systemic lupus erythematosus, lung, pleuropulmonary involvement, pulmonary vascular involvement, cancer, respiratory infection, pulmonary damage, respiratory mortality

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6942(09)00003-5

doi:10.1016/j.berh.2009.01.002

Best Practice & Research Clinical Rheumatology
Volume 23, Issue 4 , Pages 469-480, August 2009